[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974


DOI: 10.29090/psa.2022.06.22.236Pharm Sci Asia 2022; 49(6), 543-549

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer

Jukapun Yoodee1,2, Chiraphon Detma1, Onuma Lappanawan1, Worachaya Pengthina1,2*

1 Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand
2 Pharmaceutical Care Training Center (PCTC), Faculty of Pharmacy, Chiang mai University, Chiang Mai, Thailand

Androgen receptor signaling inhibitor (ARSI) therapy plays an important role in treating advanced prostate cancer. However, in Thailand, the efficacy and safety data of ARSI therapy remain limited. This study aimed to assess the efficacy and safety of ARSI therapy to treat patients with metastatic castration na?ve prostate cancer. We collected data from electronic medical records based on disease progression and any reported adverse events. The primary outcome was progression-free survival (PFS) after initiating ARSI therapy. Secondary outcome was PFS according to abiraterone and enzalutamide, risk factors associated with PFS of ARSI therapy and adverse events. A total of 49 eligible patients were enrolled having received ARSI therapy (abiraterone or enzalutamide) to treat metastatic prostate cancer. The median time to follow-up was 17 months (interquartile range, 12-31). PFS among patients treated with ARSI therapy was 22 months (95% confidence interval [CI], 17-33), PFS among patients with abiraterone and enzalutamide was 21 and 23 months, respectively (hazard ratio [HR], 0.48; 95% CI, 0.17-1.41, P=0.185). Patients with Eastern Cooperative Group status 1-2 exhibited significantly decreased risk of disease progression (HR, 0.44; 95% CI, 0.20-0.96, P=0.038). The common adverse events included hypertension and fluid retention and edema. In conclusion, abiraterone and enzalutamide showed a trend to improve PFS among patients with metastatic castration naive prostate cancer. Adverse events were rarely reported, and patients were able to tolerate treatment.


Androgen receptor signaling inhibitor, Castration naive, Prostate cancer, Abiraterone, Enzalutamide

Download full paper (PDF File size: 1,082.93 KB.)

November-December 2022

See other volume


September-October 2022

See other volume


July-August 2022

See other volume


May-June 2022

See other volume


March-April 2022

See other volume


January-February 2022

See other volume


Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
All Volumes & Issues
Submit Online
Contact us
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register

Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2024
    Faculty of Pharmacy, Mahidol University, THAILAND

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.